181 related articles for article (PubMed ID: 38793756)
1. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
3. Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants.
Nagasawa N; Kimura R; Akagawa M; Shirai T; Sada M; Okayama K; Sato-Fujimoto Y; Saito M; Kondo M; Katayama K; Ryo A; Kuroda M; Kimura H
Microorganisms; 2023 Sep; 11(9):. PubMed ID: 37764181
[TBL] [Abstract][Full Text] [Related]
4. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
[TBL] [Abstract][Full Text] [Related]
5. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
6. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
7. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
[TBL] [Abstract][Full Text] [Related]
8. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
9. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
10. Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants.
Roy U
Pathogens; 2023 Dec; 13(1):. PubMed ID: 38276156
[TBL] [Abstract][Full Text] [Related]
11. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
12. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
13. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
[TBL] [Abstract][Full Text] [Related]
15. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
[TBL] [Abstract][Full Text] [Related]
16. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine.
Li W; Zhao T; Tao B; Zhao L; Xiao H; Ding X; Li C; Chen L; Cheng H; Lou Y; Chen Y; Wu C
Hum Vaccin Immunother; 2023 Aug; 19(2):2264589. PubMed ID: 37846840
[TBL] [Abstract][Full Text] [Related]
17. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
[TBL] [Abstract][Full Text] [Related]
19. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
[TBL] [Abstract][Full Text] [Related]
20. An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
Li T; Luo D; Ning N; Wang X; Zhang L; Yang X; Li D; Sun Y; Yu W; Wei W; Wang H
Emerg Microbes Infect; 2023 Dec; 12(1):2207670. PubMed ID: 37272331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
